A T-cell–redirecting bispecific monoclonal antibody that binds CD20 on B cells and CD3 on T cells (2:1 CD20:CD3 format), forming an immune synapse that activates cytotoxic T cells to kill CD20+ malignant B cells.
CD20xCD3 bispecific monoclonal antibody (2:1 CD20:CD3) that binds CD20 on B cells and CD3 on T cells, forming an immune synapse that activates T-cell receptor signaling and redirects cytotoxic T cells to kill CD20-positive malignant B cells.
YES
DIRECT
Bispecific antibody bridges CD20 on B cells and CD3 on T cells, forming an immune synapse that activates T cells to release perforin/granzymes and kill CD20+ cells.
A T-cell–redirecting bispecific monoclonal antibody that binds CD20 on B cells and CD3 on T cells (2:1 CD20:CD3 format), forming an immune synapse that activates cytotoxic T cells to kill CD20+ malignant B cells.
CD20xCD3 bispecific monoclonal antibody (2:1 CD20:CD3) that binds CD20 on B cells and CD3 on T cells, forming an immune synapse that activates T-cell receptor signaling and redirects cytotoxic T cells to kill CD20-positive malignant B cells.
NO
INDIRECT
Binds CD3 on T cells to recruit/activate them; activated T cells kill CD20+ B cells via immune-synapse–mediated cytotoxicity (perforin/granzymes). CD3+ T cells are engaged, not killed.
Type I chimeric anti-CD20 monoclonal antibody that depletes CD20+ B cells via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Chimeric type I anti‑CD20 monoclonal antibody that binds CD20 on B cells and induces B‑cell depletion primarily via antibody‑dependent cellular cytotoxicity (ADCC) and complement‑dependent cytotoxicity (CDC), leading to lysis/apoptosis of CD20+ cells.
YES
DIRECT
Rituximab binds CD20 on B cells and recruits effector mechanisms—ADCC via Fcγ receptor–bearing cells (e.g., NK cells) and complement-dependent cytotoxicity via C1q activation—resulting in lysis/apoptosis of CD20+ cells.
Also referred to as FDA022-BB05, this is an intravenous HER2-targeted monoclonal antibody–drug conjugate (ADC) that binds HER2 on tumor cells, is internalized, and releases an intracellular cytotoxic payload; it may also contribute to HER2 pathway blockade and Fc-mediated effector functions.
HER2-targeted monoclonal antibody–drug conjugate that binds HER2 on tumor cells, is internalized, and releases an intracellular cytotoxic payload to kill the cells; may also inhibit HER2 signaling and mediate Fc-dependent effector functions (e.g., ADCC).
YES
DIRECT
The HER2-targeted ADC binds HER2, is internalized, and releases an intracellular cytotoxic payload that kills the cell; Fc-mediated ADCC may also contribute.
Fully human IgG1κ anti-CD20 monoclonal antibody for relapsing multiple sclerosis; binds a membrane‑proximal CD20 epitope on B cells, inducing B‑cell depletion via complement‑dependent cytotoxicity and Fc‑mediated ADCC/ADCP, reducing pathogenic antigen presentation and proinflammatory cytokine signaling; administered subcutaneously.
Fully human anti-CD20 IgG1κ monoclonal antibody that binds a membrane-proximal CD20 epitope on B cells and depletes them via complement-dependent cytotoxicity and Fc-mediated ADCC/ADCP, thereby reducing pathogenic B-cell antigen presentation and proinflammatory cytokine signaling.
YES
DIRECT
Ofatumumab binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC/ADCP, leading to direct lysis and clearance of CD20+ cells.